Dan Cao

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Radiation Induced

Placebo Controlled

Epidermal Growth Factor Receptor

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Chenyan Zhang, Heqi Yang, Chen Chang, Ruizhen Li, Junjie Xiong, De-Ying Kang, Du He, Xi-Jiao Liu, Ke Cheng, Dan Cao
Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ open 14 (7) (2024)
Chenyan Zhang, Heqi Yang, Chen Chang, Ruizhen Li, Junjie Xiong, De-Ying Kang, Du He, Xi-Jiao Liu, Ke Cheng, Dan Cao
Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ open 14 (7) (2024)
Chenyan Zhang, Heqi Yang, Chen Chang, Ruizhen Li, Junjie Xiong, De-Ying Kang, Du He, Xi-Jiao Liu, Ke Cheng, Dan Cao
Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ open 14 (7) (2024)
Chenyan Zhang, Heqi Yang, Chen Chang, Ruizhen Li, Junjie Xiong, De-Ying Kang, Du He, Xi-Jiao Liu, Ke Cheng, Dan Cao
Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ open 14 (7) (2024)